Compare PCYO & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCYO | TNXP |
|---|---|---|
| Founded | 1976 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.5M | 199.7M |
| IPO Year | 1995 | 2008 |
| Metric | PCYO | TNXP |
|---|---|---|
| Price | $11.50 | $12.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 68.5K | ★ 448.1K |
| Earning Date | 04-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.50 | ★ 91.75 |
| EPS | ★ 0.36 | N/A |
| Revenue | $1,227,787.00 | ★ $13,107,000.00 |
| Revenue This Year | N/A | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | $31.78 | ★ N/A |
| Revenue Growth | ★ 171.54 | 29.85 |
| 52 Week Low | $9.71 | $9.40 |
| 52 Week High | $12.44 | $39.45 |
| Indicator | PCYO | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 66.57 | 59.67 |
| Support Level | $10.51 | $11.98 |
| Resistance Level | $11.58 | $13.36 |
| Average True Range (ATR) | 0.30 | 0.85 |
| MACD | 0.07 | 0.21 |
| Stochastic Oscillator | 92.02 | 72.75 |
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in three business segments namely Water and wastewater resource development, Land development, and the Single-Family Rental Segment. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.